MGT Inc. Login  |  Register  |  Newsletter Subscription  |  Cart 
MGT Inc.
MGT Inc.
MGT Inc.
     

Products


Vectors Vectors
OliGlo OliGloTM Nucleic Acid Labeling Kits
Enzyme Substrates and Kits Enzyme Substrates and Kits
Enzyme Inhibitors Enzyme Inhibitors
MGT Detection Kits MGT Detection Kits
Cell Regulatory Substrates Cell Regulatory Substrates
Special Labeling Reagents Special Labeling Reagents
Lipids Lipids
Carbohydrates/Oligosaccharides Carbohydrates/Oligosaccharides  
Fluorescent Reagents Fluorescent Reagents
M1080 - C12-NBD, free acid (12-(7-Nitrobenzofurazan-4-ylamino)dodecanoic acid)
(12-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)dodecanoic acid; NBD-aminododecanoic acid)


Molecular Weight: 378.43

Storage: F, L

[C=Cold D=Desiccated F=Frozen L=Light Sensitive RT=Room Temperature]

Soluble: DMF, DMSO, MeOH

Absorption: (in nm) 466

Emission: (in nm) 530

Extinction (103): 24

Molecular Formula: C18H26N4O5

CAS Number: [96801-39-7]

Alternative Name: 12-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)dodecanoic acid; NBD-aminododecanoic acid

Unit Price (USD): 100 mg $121.54

Bulk Price/unit (when you buy 5 or more): $97.23

Description:
Useful fluorescent probe for fatty acid and carrier protein binding sites.

References:

  • "Purification and characterization of a neutral ceramidase from mouse liver. A single protein catalyzes the reversible reaction in which ceramide is both hydrolyzed and synthesized." Tani M, Okino N, Mitsutake S, Tanigawa T, Izu H, Ito M. J Biol Chem 275: 3462-3468 (2000).
  • "Probing the ligand binding sites of fatty acid and sterol carrier proteins: effects of ethanol." Schroeder F, Myers-Payne SC, Billheimer JT, Wood WG. Biochemistry 34(37): 11919-27 (1995).
  • "Lateral diffusion of lipids in model and natural membranes." Tocanne JF, Dupou-Cezanne L, Lopez A. Prog Lipid Res 33: 203-237 (1994).
  • "Large-scale preparation of asymmetrically labeled fluorescent lipid vesicles." Dao HN, McIntyre JC, Sleight RG. Anal Biochem 196: 46-53 (1991).
  • "Human acid beta-glucosidase: use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites." Osiecki-Newman K, Fabbro D, Legler G, Desnick RJ, Grabowski GA. Biochim Biophys Acta 15: 87-100 (1987).
  • "Prenatal diagnosis of Krabbe disease using a fluorescent derivative of galactosylceramide." Zeigler M, Zlotogora J, Regev R, Dagan A, Gatt S, Bach G. Clin Chim Acta 142: 313-318 (1984).
  • "Gaucher type I (Ashkenazi) disease: a new method for heterozygote detection using a novel fluorescent natural substrate." Grabowski GA, Dinur T, Gatt S, Desnick RJ. Clin Chim Acta 124: 123-135 (1982).


©2012 Marker Gene Technologies, Inc. Published by Marker Gene Technologies, Inc., The University of Oregon Riverfront Research Park, 1850 Millrace Drive, Eugene, Oregon 97403-1992 USA. All rights reserved. For information on the use or copying of the material contained in this document, please contact us at techservice@markergene.com.